Palmitoylethanolamide Reduces Colon Cancer Cell Proliferation and Migration, Influences Tumor Cell Cycle and Exerts In Vivo Chemopreventive Effects

Pagano, Ester; Venneri, Tommaso; Lucariello, Giuseppe; Cicia, Donatella; Brancaleone, Vincenzo; Nanì, Maria Francesca; Cacciola, Nunzio Antonio; Capasso, Raffaele; Izzo, Angelo A.; Borrelli, Francesca; Romano, Barbara

doi:10.3390/cancers13081923

Cited by 28 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is evidence that drugs targeting microtubules usually induce cell cycle arrest ( 24 , 25 ). Since we have demonstrated that microtubule protein polymerization was disrupted by 6h , further experiments were necessary to investigate the effect of 6h on the cell cycle of NSCLC cells.…”

Section: Resultsmentioning

confidence: 99%

A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non–small cell lung cancers

Huang

Zhou

et al. 2022

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non–small cell lung cancers

Huang

Zhou

et al. 2022

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…In fact, CBs have been proposed as novel anti-tumor targets in patients with non-small cell lung cancer (NSCLC) and breast cancer [50,51]. While the mechanism remains poorly defined, palmitoylethanolamide (PEA) is an endogenous fatty acid amide related to CB-Rs that facilitates an anti-inflammatory effect [52]. In fact, ultra-micronized PEA (um-PEA) has been shown to inhibit tumor cell proliferation and tumor cell migration both in vitro and in vivo [52].…”

Section: Discussionmentioning

confidence: 99%

Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping

Xiao

Zhang

Cloyd

et al. 2022

Cancers

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy, and there is a need for effective systemic therapies. Gene expression profile-based analyses may allow for efficient screening of potential drug candidates to serve as novel therapeutics for patients with ICC. The RNA expression profile of ICC and normal biliary epithelial cells were downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Function annotation and enrichment pathway analyses of the differentially expressed genes (DEGs) were finished using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A weighted gene co-expression network (WGCN) was constructed by WGCN analysis (WGCNA). Key genes from the DEGs and co-expression gene modules were analyzed to generate a protein–protein interaction (PPI) network. The association between the top 10 screened hub genes and the overall and disease-free survival of ICC patients was examined. The Connectivity Map (cMap) analysis was performed to identify possible drugs for ICC using hub genes. A total of 151 key genes were selected from the overlapping genes of 1287 GSE-DEGs, 8183 TCGA-DEGs and 1226 genes in the mixed modules. A total of 10 hub genes of interest (CTNNB1, SPP1, COL1A2, COL3A1, SMAD3, SRC, VCAN, PKLR, GART, MRPS5) were found analyzing protein–protein interaction. Using the cMap, candidate drugs screened with potential efficacy for ICC included three tyrosine kinase inhibitors (dasatinib, NVP-BHG712, tivantinib), two cannabinoid receptor agonists (palmitoylethanolamide, arachidonamide), two antibiotics (moxifloxacin, amoxicillin), one estrogen receptor agonist (levonorgestrel), one serine/threonine protein kinase inhibitor (MK-2206) and other small molecules. Key genes from network and PPI analysis allowed us to identify potential drugs for ICC. The identification of novel gene expression profiles and related drug screening may accelerate the identification of potential novel drug therapies for ICC.

show abstract

“…It is one of the few compounds to reduce noradrenaline release that is involved in sympathetically maintained pain (a secondary pain to neuropathic pain). The compound can reduce liver fibrosis [46] and tumor cell proliferation [47].…”

Section: Palmitoylethanolamidementioning

confidence: 99%

Regenerative Medicine to Reduce the Side Effects from Radiotherapy Causing Skin Cancer, Fibrosis, Neuropathic Pain and Hair Loss

Vickers¹,

Liang²,

Vickers³

et al. 2021

JCT

View full text Add to dashboard Cite

Surgery, chemotherapy and radiotherapy are the gold standard treatments used for cancer. Side effects from medical radiation can be significant, particularly external beam therapy to the breast, and head and neck regions causing fibrosis, secondary skin cancer, hair loss, oral mucositis and neuropathic pain. There is significant psychological stress, depression, anxiety and loss of self esteem particularly for female patients. Similar types of space radiation are known to damage the health of astronauts. Current treatments for scarring, tissue loss, hair loss and neuropathic pain are a high priority but inadequate. Regenerative medicine is a new and comprehensive approach to potentially treat complex medical conditions from radiation damage. Regenerative medicine combines a systematic evidence based approach with the use of herbal medicine, stem cells, peptides and 3D tissue engineering. These fields use sophisticated technology to identify the respective molecular mechanisms of upregulation and protection of healthy cells and down regulation of cancer cells. The regenerative medicine strategies of stem cells and plant polyphenols suggest there is significant potential for rapid clinical translation to alleviate the side effects associated with radiotherapy.

show abstract

Palmitoylethanolamide Reduces Colon Cancer Cell Proliferation and Migration, Influences Tumor Cell Cycle and Exerts In Vivo Chemopreventive Effects

Cited by 28 publications

References 32 publications

A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non–small cell lung cancers

A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non–small cell lung cancers

Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping

Regenerative Medicine to Reduce the Side Effects from Radiotherapy Causing Skin Cancer, Fibrosis, Neuropathic Pain and Hair Loss

Contact Info

Product

Resources

About